Merck wins record US$2.5b patent verdict against Gilead
New York
GILEAD Sciences Inc - the biopharmaceutical giant with a market capitalisation of US$100 billion, which Singapore's Temasek Holdings owns 1.05 per cent of, was told by a US federal jury to pay US$2.54 billion to Merck & Co for using a patented invention as the basis for its blockbuster drugs for the potentially deadly liver disease hepatitis C. This is the biggest patent-infringement verdict in US history.
The jury in Wilmington, Delaware, deliberated for less than two hours and rejected Gilead's arguments that Merck's patent is invalid. The judge in the case had already decided that Merck's patent was infringed by Gilead'…
KEYWORDS IN THIS ARTICLE
BT is now on Telegram!
For daily updates on weekdays and specially selected content for the weekend. Subscribe to t.me/BizTimes
Companies & Markets
Meta releases early versions of its Llama 3 AI model
Seatrium unit ordered to pay US$108 million in arbitration over equipment supply contracts
TSMC estimates losses of US$92.4 million due to Taiwan earthquake
Marina Bay Sands Q1 profit surges 51.5% to US$597 million on tourism boom
US: Wall St opens higher as some chip stocks bounce back after selloff
Blackstone reports 1% rise in Q1 earnings